Date: 2015-03-19
Type of information: Collaboration agreement
Compound: multi-specific antibodies addressing diabetes, obesity and autoimmune indications
Company: Intarcia Therapeutics (USA - CA) Numab (Switzerland)
Therapeutic area: Autoimmune diseases - Metabolic diseases
Type agreement: collaboration
Action mechanism: multi-specific antibody
Disease: diabetes, obesity and autoimmune diseases
Details: * On March 19, 2015, Intarcia Therapeutics and Numab announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. Intarcia will be responsible for the development, manufacturing and commercialization of all products stemming from the collaboration.
Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics, commented: “We believe the unique characteristics of Numab’s antibody technology fit perfectly with our disruptive platform technologies, which have the potential to eliminate life-long injections and produce best-in-disease once- or twice-yearly medicines. Now is the time, as we finish our phase 3 program for ITCA 650 in type 2 diabetes, to take this important strategic step to enhance and expand our pipeline. This collaboration reinforces Intarcia’s ongoing priority to develop game-changing therapeutics that address major unmet medical needs such as suboptimal efficacy as well as poor compliance and adherence.”
Financial terms: Under the terms of the collaboration, Numab is eligible to receive upfront and contingent milestone payments, as well as tiered single to low double-digit royalties on any sales resulting from collaborative efforts. Intarcia has the option to extend the collaboration beyond the initial assets and targets as well as the opportunity to purchase a strategic interest in Numab AG at a pre-defined time point.
Latest news:
